Cargando…

Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances

Primary liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide. After surgery, up to 70% of patients experience relapses. The current first-line therapy for advanced cases of hepatocellular carcinoma (HCC) comprises sorafenib and lenva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Charneau, Jimmy, Suzuki, Toshihiro, Shimomura, Manami, Fujinami, Norihiro, Nakatsura, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424432/ https://www.ncbi.nlm.nih.gov/pubmed/34513746 http://dx.doi.org/10.2147/JHC.S291558

Ejemplares similares

Development of antigen‐prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse
por: Charneau, Jimmy, et al.
Publicado: (2022)

Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model
por: Fujinami, Norihiro, et al.
Publicado: (2016)

Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate
por: SUGAI, SHIORI, et al.
Publicado: (2016)

Peptide vaccine as an adjuvant therapy for glypican‐3‐positive hepatocellular carcinoma induces peptide‐specific CTLs and improves long prognosis
por: Taniguchi, Masatake, et al.
Publicado: (2020)

Peptide vaccines for hepatocellular carcinoma
por: Nobuoka, Daisuke, et al.
Publicado: (2013)

Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
por: TADA, YOSHITAKA, et al.
Publicado: ( 201)

Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes
por: SAWADA, YU, et al.
Publicado: (2014)

Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery
por: Miura, Masahiro, et al.
Publicado: (2020)

A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012)

Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery
por: Akazawa, Yu, et al.
Publicado: (2019)

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Plasma and tumoral glypican‐3 levels are correlated in patients with hepatitis C virus‐related hepatocellular carcinoma
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: Two case reports
por: Suzuki, Shiro, et al.
Publicado: (2014)

Identification of an H2-K(b) or H2-D(b) restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide
por: IWAMA, TATSUAKI, et al.
Publicado: (2013)

A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
por: OFUJI, KAZUYA, et al.
Publicado: (2014)

Time-lapse imaging assay using the BioStation CT: A sensitive drug-screening method for three-dimensional cell culture
por: Sakamoto, Ruriko, et al.
Publicado: (2015)

Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case
por: Sawada, Yu, et al.
Publicado: (2013)

Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer
por: Imaizumi, Ken, et al.
Publicado: (2019)

Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma
por: Suzuki, Shiro, et al.
Publicado: (2016)

Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma
por: Ukai, Mayu, et al.
Publicado: (2021)

Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2014)

Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2016)

Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy
por: Nobuoka, Daisuke, et al.
Publicado: (2012)

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
por: Sawada, Yu, et al.
Publicado: (2016)

Recent advances in the imaging of hepatocellular carcinoma
por: You, Myung-Won, et al.
Publicado: (2015)

Recent Advances in Immunotherapy for Hepatocellular Carcinoma
por: Nakano, Shigeharu, et al.
Publicado: (2020)

Recent Advancements for the Treatment of Hepatocellular Carcinoma
por: Nouso, Kazuhiro
Publicado: (2023)

Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma
por: Aitcheson, Gabriella, et al.
Publicado: (2021)

Component with abundant immune‐related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis
por: Yagi, Naoki, et al.
Publicado: (2022)

Recent Advances in Liver Resection for Hepatocellular Carcinoma
por: Morise, Zenichi, et al.
Publicado: (2014)

Recent advances of GOLM1 in hepatocellular carcinoma
por: Yan, Jiuliang, et al.
Publicado: (2020)

Recent advances in systemic therapy for hepatocellular carcinoma
por: Zhang, Huajun, et al.
Publicado: (2022)

Recent advances in the surgical management of hepatocellular carcinoma
por: Glantzounis, Georgios K., et al.
Publicado: (2021)

Circular RNAs in hepatocellular carcinoma: Recent advances
por: Niu, Zhao-Shan, et al.
Publicado: (2022)

Recent Advances in Hepatocellular Carcinoma Treatment with Radionuclides
por: Liu, Ruiqi, et al.
Publicado: (2022)

Hepatitis Virus and Hepatocellular Carcinoma: Recent Advances
por: Shen, Chen, et al.
Publicado: (2023)

Recent advances in recurrent hepatocellular carcinoma therapy
por: Gao, Yu-Xue, et al.
Publicado: (2023)

Recent Advances in Locoregional Therapy of Hepatocellular Carcinoma
por: Podlasek, Anna, et al.
Publicado: (2023)

Higher human lymphocyte antigen class I expression in early‐stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes
por: Akazawa, Yu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_os1lqmpaeo2rt0mc79u1f1v3no